Evidence map›Paper›PMID 41884254›Full record

ReviewWorld journal of nephrology2026

Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease.

Olesya Ilkun, Firouzeh Jazayeri, Amir Kazory

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olesya IlkunDivision of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL 32610-0224, United States. olesya.ilkun@medicine.ufl.edu.
Firouzeh JazayeriUF Health Outpatient Dialysis Unit, UF Health, Gainesville, FL 32610, United States.
Amir KazoryDivision of Nephrology, Hypertension, and Renal Transplantation, University of Florida College of Medicine, Gainesville, FL 32610, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive loss of kidney function in chronic kidney disease and end-stage kidney disease leads to distinct pathological changes in mineral and bone metabolism. Historically, the management of these patients focused on lowering their serum phosphate, parathyroid hormone, and normalizing serum calcium. However, persistently high morbidity and mortality of these patients from cardiovascular diseases and after bone fractures call for more specific therapies. Here, we summarize established and emerging therapies for managing the three main domains of mineral bone disorder in patients with advanced chronic kidney disease and end-stage kidney disease: Control of mineral imbalance, management of vascular disease or other soft tissue calcifications, and management of bone disorders.

Indexed as

Cardiovascular diseaseChronic kidney diseaseEnd-stage kidney diseaseMineral bone disorderParathyroid hormone

Identifiers

PMID41884254
PMCPMC13010344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.